Xtant Medical appoints Mark Schallenberger as COO effective Jan 16, 2023

Xtant Medical Holdings, Inc.

Mark Schallenberger, previously COO at Surgenex, appointed COO at Xtant Medical effective Jan 16, 2023.
Annual base salary of $400,000 with bonus of up to 50% of base salary; option for 105,000 shares and RSUs for 89,000 shares.
Role is newly created, focused on operational modernization and product development.
Previously served at Xtant (formerly Bacterin) as Director of Scientific Affairs from 2010-2016.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark A. Schallenberger

Chief Operations Officer

XTNT · Xtant Medical Holdings, Inc.

Effective: 2023-01-16
Filed: January 9, 2023, 6:59 PM ET

On January 9, 2023, Xtant Medical Holdings, Inc. (the “Company”) announced the appointment of Mark A. Schallenberger as Chief Operations Officer, effective as of January 16, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark A. Schallenberger was appointed as Chief Operations Officer at Xtant Medical Holdings, Inc..

Action: appointed
Role: Chief Operations Officer

Exact text from the filing

On January 9, 2023, Xtant Medical Holdings, Inc. (the “Company”) announced the appointment of Mark A. Schallenberger as Chief Operations Officer, effective as of January 16, 2023.

View on SEC.gov

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-000906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.